Since it is April Fools day, I thought it fitting to ask
Since it is April Fools day, I thought it fitting to ask everyone a question. What will be the next fiasco to delay LL from saving lives? Will it be a blantant rejection from the FDA? Will they try to bleed us of cash through additional trials? Will they decide all therapuetics given by shots are now illegal because needles are sharp and can be used to stab people?
How will they manipulate the rules to keep Americans from being helped by LL while bending the rules to give inferior drugs unwarranted approval?
This is actually a fun exercise and is a way to reduce the frustration with the games the FDA is playing with CYDY.
Another point that is interesting to observe is how much BS can the government get away with?
So many people have suffered needlessly from this virus. It is blatantly obvious that saving American lives by any means neccesary is not their concern.
This in turn leads to another fun activity to watch, how much covering up will mainstream media and social media perform in an attempt to keep people from learning about what is happening right under their noses?
With all this being said I am going to give my best guess at the next FDA excuse for keeping lives from being saved...
My kick the can down the road theory is in fact that the FDA outlaws needles which means we will have to make LL in a pill form, which will then require all new trials for LL at FDA mandated dosing requirements and intervals.
12 months later, when we finally jump through all the trial hoops and are still proven to be the most effective and safe therapeutic in existence, and after we have shown stat significance and fashioned our trials to be FDA BS proof, the FDA will then say that LL can not be distributed in pill form because pills present a choking hazard. You see 1 out of every 35,000,000 US residents die from choking on pills each year and it is the FDA's duty to protect the US citizens and keep them alive. Therefore we will not recieve approval.
All of this would be a funny April fools day joke if it was not actually looking more and more likely that the FDA would try to pull this kind of shit if it meant giving more time for BP to develop a competing therapeutic...
5
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
A Somber Day at NYSE: Reflecting on 9/11 September 11th grips the heart of NYSE every year, but this year's 25th-anniversary powerfully reverberates through its hallowed halls. The hustle of the trading floor halts for a moment at 9:20 AM ET, paying homage to those lost in the harrowing attacks. I've seen the markets flap in the wind of countless crises, but nothing's...
Continue Reading
A Fresh Alliance for Mental Wellness in Modeling Alright, let's shine a spotlight on a significant step in the modeling industry, a place typically less vocal about mental health. In a move that feels long overdue, Brain-Body Therapy and Mother Model Management have joined forces, marking the beginning of a collaborative effort to propel mental wellness to the forefront...
Continue Reading
Sustainability Investments: A Tale of Contrasts In the world of sustainability, a staggering $17 trillion has been poured into technologies over the past decade. That’s no chump change. But what do we have to show for it? According to Bain & Company’s latest report, this massive financial injection hasn’t exactly hit a home run. Progress, much like the stock market...
Continue Reading
Decoupling Oil Price and Production Response This oil market isn’t your usual rodeo. With Brent flirting with $100, it’s a seismic shift that’s not yielding new drills but redirecting capital to the existing infrastructure landscape. Ask yourself why we're not seeing the usual cavalry charge of new rigs. It’s simple: Pipeline mileage and producing wells have...
Continue Reading
They say you can never go home again, but don't tell that to Melissa Rivers. Rolling the dice on nostalgia and kicking off a new chapter, she's waltzing back to the Emmys red carpet for the first time in nearly 20 years. Alright, what's in it for investors? Not much—unless you're looking to invest in nostalgia. But there's something here about legacy, reinvention, and...
Continue Reading
Toss out your one-size-fits-all real estate predictions; the Q2 2026 Buy-Side Index just unveiled some real whoppers about the housing market. What we're seeing isn't your typical year-over-year growth across the board. Nope, we're seeing splits as sharp as a knife between states. Some places are shooting up in price, while others seem to be stuck in mud. Price Surges and...
Continue Reading
Korean Spirits Jari Eyes U.S. Market Entry Some stories just have that perfect 'right time, right place' vibe, and CJ Foods' recent splash with their Korean spirits brand jari is one of them. Buckle up, because this one's about a Korean distilling sensation gearing up to hit American shores with a bang. Accolades Pave the Path Jari, the premium Korean distilled spirits...
Continue Reading
Pioneering Efforts in Early-Onset Colorectal Cancer Detection The battlefield of colorectal cancer prevention just got a serious upgrade with Intus Bio grabbing a $2.7 million award. This ain't just pocket change—it's a shot at rewriting the script on how we approach early-onset colorectal cancer, the pesky number one cancer gnawing at the under-50 crowd. Partnering...
Continue Reading
Copper's New Pulse: PolarX Makes Waves in Alaska Ever hear about striking copper so rich it's practically shimmering? Well, PolarX Limited just might have hit that sweet spot up in the rugged expanses of Alaska. Let me tell you, when you're knee-deep in resources, like what they’re discovering at the Caribou Dome Project, it sure feels like you’ve struck modern-day...
Continue Reading
Revolutionizing Estate Recovery Practices Here's the scoop: DCM Services (DCMS), that big shot in estate account resolution, is hooking up with AKUVO to shake up how credit unions handle estate recoveries. This alliance is a clear nod to modernizing a process stuck in the past. Let’s face it, handling decedent and probate accounts is no cakewalk, and traditional methods...
Continue Reading
Top 5 Most Recently Viewed Articles
Cartography Biosciences Expands Its Clinical Advisory Board Cartography Biosciences, an innovative oncology company with a focus on antibody therapeutics, has taken a significant step towards enhancing its capabilities by appointing four prominent industry and academic leaders to its Clinical Advisory Board (CAB). This strategic initiative aims to augment the company's...
Continue Reading
Applied DNA Sciences Engages in Strategic Fundraising Applied DNA Sciences Inc. (NASDAQ: APDN) has embarked on an ambitious journey to secure a substantial commitment of up to $58 million. This funding is set to initiate their distinguished digital asset treasury strategy, focused on the integration of BNB, which is the native cryptocurrency of the esteemed Binance...
Continue Reading
Zepp Health Introduces Zepp App 9 Zepp Health Corporation (NYSE: ZEPP) has unveiled its latest innovation, the Zepp App 9. This smart wearable application is designed to significantly enhance the health, wellness, and fitness tracking capabilities for users of Amazfit devices. The updated application brings a variety of exciting new features tailored to deliver a more...
Continue Reading
The Changing Landscape of Low-Risk Investments Not too long ago, low-risk investment options like Treasury bills were often seen as underperformers in the financial world. While Treasuries provided a secure place for savings, they didn't offer the attractive returns that savings accounts did. Recently, however, a notable shift has taken place as interest rates have risen,...
Continue Reading
Market Insights on BellRing Brands Options In the dynamic world of investment, it has been observed that financial giants are making noteworthy bearish moves concerning BellRing Brands Inc. Our in-depth analysis of recent options trading activity surrounding BellRing Brands (BRBR) has uncovered a pattern of unusual trades that cannot be ignored. Unpacking the Trading Data...
Continue Reading